Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
35,033
archived clinical trials in
Lung Cancer

Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
San Diego, CA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Boca Raton, FL
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Honolulu, HI
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Honolulu, HI
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Evanston, IL
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Bethesda, MD
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Boston, MA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Lebanon, NH
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Charlotte, NC
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
Clinical Research Facility
mi
from
Washington, WA
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
Clinical Research Facility
mi
from
Washington, WA
Click here to add this to my saved trials
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated:  3/8/2018
mi
from
Darlinghurst,
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor
Status: Enrolling
Updated: 3/8/2018
mi
from
Darlinghurst,
Click here to add this to my saved trials
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated:  3/9/2018
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated: 3/9/2018
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated:  3/9/2018
Clinical Trials and Research Associates, Inc.
mi
from
Montebello, CA
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated: 3/9/2018
Clinical Trials and Research Associates, Inc.
mi
from
Montebello, CA
Click here to add this to my saved trials
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated:  3/9/2018
Innovative Medical Research of South Florida, Inc
mi
from
Miami, FL
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated: 3/9/2018
Innovative Medical Research of South Florida, Inc
mi
from
Miami, FL
Click here to add this to my saved trials
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated:  3/9/2018
Crescent City Research Consortiom
mi
from
Marrero, LA
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated: 3/9/2018
Crescent City Research Consortiom
mi
from
Marrero, LA
Click here to add this to my saved trials
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated:  3/9/2018
Interlakes Foundation, Incorporated
mi
from
Rochester, NY
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated: 3/9/2018
Interlakes Foundation, Incorporated
mi
from
Rochester, NY
Click here to add this to my saved trials
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated:  3/9/2018
Lehigh Valley Hospital / Lehigh Valley Health Network
mi
from
Allentown, PA
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated: 3/9/2018
Lehigh Valley Hospital / Lehigh Valley Health Network
mi
from
Allentown, PA
Click here to add this to my saved trials
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated:  3/9/2018
South Texas Institute of Cancer, Northwest Cancer Center
mi
from
Corpus Christi, TX
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated: 3/9/2018
South Texas Institute of Cancer, Northwest Cancer Center
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated:  3/9/2018
Instituto de Medicina Nuclear de Bahía Blanca
mi
from
Bahía Blanca,
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation
Status: Enrolling
Updated: 3/9/2018
Instituto de Medicina Nuclear de Bahía Blanca
mi
from
Bahía Blanca,
Click here to add this to my saved trials
Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy (MSK10-134)
Status: Enrolling
Updated:  3/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy (MSK10-134)
Status: Enrolling
Updated: 3/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy (MSK10-134)
Status: Enrolling
Updated:  3/9/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134
Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy (MSK10-134)
Status: Enrolling
Updated: 3/9/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Status: Enrolling
Updated:  3/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
Status: Enrolling
Updated: 3/9/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Status: Enrolling
Updated:  3/11/2018
Massachusetts General Hospital
mi
from
Boston, MA
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Status: Enrolling
Updated: 3/11/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Status: Enrolling
Updated:  3/11/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Status: Enrolling
Updated: 3/11/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Status: Enrolling
Updated:  3/11/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Status: Enrolling
Updated: 3/11/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Status: Enrolling
Updated:  3/11/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Status: Enrolling
Updated: 3/11/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  3/11/2018
Commonwealth Cancer Center
mi
from
Danville, KY
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 3/11/2018
Commonwealth Cancer Center
mi
from
Danville, KY
Click here to add this to my saved trials
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  3/11/2018
University of Kentucky
mi
from
Lexington, KY
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 3/11/2018
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  3/11/2018
University of Louisville Hospital
mi
from
Louisville, KY
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 3/11/2018
University of Louisville Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  3/11/2018
Owensboro Medical Health System
mi
from
Owensboro, KY
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer
Allogeneic Cellular Vaccine 1650-G for Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 3/11/2018
Owensboro Medical Health System
mi
from
Owensboro, KY
Click here to add this to my saved trials
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study
Status: Enrolling
Updated:  3/12/2018
Beaumont Hospital, Royal Oak
mi
from
Royal Oak, MI
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study
Status: Enrolling
Updated: 3/12/2018
Beaumont Hospital, Royal Oak
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study
Status: Enrolling
Updated:  3/12/2018
Thomas Jefferson University [Kimmel Cancer Center]
mi
from
Philadelphia, PA
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study
Status: Enrolling
Updated: 3/12/2018
Thomas Jefferson University [Kimmel Cancer Center]
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study
Status: Enrolling
Updated:  3/12/2018
Prinses Margaret Hospital
mi
from
Toronto,
Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously
VOLUMES Treatment of Larger Tumor Volumes or ≥ 2 Lung Tumors Simultaneously in Lung Cancer Patients Using SBRT in a Mean-lung Dose Escalation Study
Status: Enrolling
Updated: 3/12/2018
Prinses Margaret Hospital
mi
from
Toronto,
Click here to add this to my saved trials
Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC
Phase II Trial of Pulsed Paclitaxel With Concurrent Radiotherapy,and Adjuvant Chemotherapy in Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/13/2018
Brody School of Medicine at East Carolina University
mi
from
Greenville, NC
Phase II Trial of Pulsed Taxol With Concurrent Thoracic Radiotherapy, & Adjuvant Chemo in Stage III NSCLC
Phase II Trial of Pulsed Paclitaxel With Concurrent Radiotherapy,and Adjuvant Chemotherapy in Stage III Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/13/2018
Brody School of Medicine at East Carolina University
mi
from
Greenville, NC
Click here to add this to my saved trials
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Status: Enrolling
Updated:  3/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Status: Enrolling
Updated: 3/13/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Treating NSCLC Minimal Stage IV With Curative Intent
A Pilot Study Treating Patients With Minimal Stage IV Non-Small Cell Lung Cancer (NSCLC) With Curative Intent
Status: Enrolling
Updated:  3/13/2018
Leo W. Jenkins Cancer Center
mi
from
Greenville, NC
Treating NSCLC Minimal Stage IV With Curative Intent
A Pilot Study Treating Patients With Minimal Stage IV Non-Small Cell Lung Cancer (NSCLC) With Curative Intent
Status: Enrolling
Updated: 3/13/2018
Leo W. Jenkins Cancer Center
mi
from
Greenville, NC
Click here to add this to my saved trials
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
Phase 2 Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)
Status: Enrolling
Updated:  3/15/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
Phase 2 Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)
Status: Enrolling
Updated: 3/15/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
Phase 2 Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)
Status: Enrolling
Updated:  3/15/2018
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer
Phase 2 Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514)
Status: Enrolling
Updated: 3/15/2018
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Status: Enrolling
Updated:  3/15/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
Status: Enrolling
Updated: 3/15/2018
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC)
A Biomarker-Integrated Study in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  3/15/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
BATTLE Program: Umbrella Protocol for Patients With Non-Small Cell Lung Cancer (NSCLC)
A Biomarker-Integrated Study in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 3/15/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/16/2018
Yale Universtiy
mi
from
New Haven, CT
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/16/2018
Yale Universtiy
mi
from
New Haven, CT
Click here to add this to my saved trials
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  3/16/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 3/16/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated:  3/16/2018
Mount Siani Medical Center
mi
from
Miami, FL
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated: 3/16/2018
Mount Siani Medical Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated:  3/16/2018
St. Elizabeth's Healthcare
mi
from
Edgewood, KY
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated: 3/16/2018
St. Elizabeth's Healthcare
mi
from
Edgewood, KY
Click here to add this to my saved trials
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated:  3/16/2018
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated: 3/16/2018
Metro Minnesota Community Oncology Research Consortium
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated:  3/16/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated: 3/16/2018
Nebraska Methodist Hospital
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated:  3/16/2018
Englewood Hospital and Medical Center
mi
from
Englewood, NJ
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated: 3/16/2018
Englewood Hospital and Medical Center
mi
from
Englewood, NJ
Click here to add this to my saved trials
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated:  3/16/2018
Rapid City Regional Hospital/Regional Cancer Care Institute
mi
from
Rapid City, SD
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study
Status: Enrolling
Updated: 3/16/2018
Rapid City Regional Hospital/Regional Cancer Care Institute
mi
from
Rapid City, SD
Click here to add this to my saved trials
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer
Status: Enrolling
Updated:  3/16/2018
Des Moines Oncology Research Association
mi
from
Des Moines, IA
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer
Status: Enrolling
Updated: 3/16/2018
Des Moines Oncology Research Association
mi
from
Des Moines, IA
Click here to add this to my saved trials
Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
Phase I/IIA: Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
Status: Enrolling
Updated:  3/19/2018
The Mayo Clinic
mi
from
Rochester, MN
Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
Phase I/IIA: Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer
Status: Enrolling
Updated: 3/19/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients With Advanced NSCLC
Status: Enrolling
Updated:  3/19/2018
Massachusetts General Hospital
mi
from
Boston, MA
Integrated Versus Standard Palliative Care in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients With Advanced NSCLC
Status: Enrolling
Updated: 3/19/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials